. 2023 Nov 21;41(1):113–129. doi: 10.1007/s12325-023-02714-8

Table 1.

Criteria for definition of tumour progression used in phase III clinical trials with gastro-entero-pancreatic neuroendocrine tumour treatments

Study/treatment	Criteria	Definition
PROMID [15] Octreotide long-acting	RECIST 1.0 [16]	Increase of ≥ 20% in the sum of the longest diameter of target lesions, taking as a reference the smallest sum on longest diameter recorded since the treatment started
PROMID [15] Octreotide long-acting	RECIST 1.0 [16]	The appearance of ≥ 1 new lesion(s)
CLARINET [17] Lanreotide Autogel	WHO [14]	Increase of ≥ 25% in the size of one or more measurable lesions
CLARINET [17] Lanreotide Autogel	WHO [14]	The appears of new lesions
NETTER-1 [4] ¹⁷⁷Lu-octreotate	RECIST 1.1 [13]	Increase of ≥ 20% in the sum of diameters of target lesions, taking as a reference the smallest sum on study (including the baseline sum if that is the smallest on study)
		The increase must also demonstrate an absolute increase of ≥ 5 mm
		The appearance of ≥ 1 new lesion(s)

RECIST response evaluation criteria in solid tumours, WHO World Health Organization